BioSpace News Archive

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), today announced the decision to discontinue the OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to enrollment feasibility.

Galectin Therapeutics Inc.(NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022 Annual Meeting of Stockholders to be held on Thursday, December 1, 2022 beginning at 11:00 a.m. ET.

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to proceed with clinical study of [18F]FAPI-74, its lead fluorine-18 labelled Fibroblast Activation Protein Inhibitor (FAPI) product.

Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors.

BigHat Biosciences, Inc. today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs.

Microbiotica announces a change of leadership as Mike Romanos hands over the Microbiotica CEO role to current COO, Tim Sharpington.

Amulet Capital Partners, LP today announced that it has acquired United Vein & Vascular Centers (“UVVC” or the “Company”), a leading provider of high-quality vascular care treatment services.

Agilent Technologies Inc. announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced security and efficiency.

Verismo Therapeutics, a clinical-stage CAR-T company, Penn spinout, and pioneer of the novel KIR-CAR platform technology, announced its new Research and Development Center located at CIC Philadelphia.

Zymeworks Inc. today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals has expired.